Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07553442 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran
A Phase 2 study, sponsored by Alnylam Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 93
- Enrollment target
NCT07553442: Recruiting Phase 2 study, sponsored by Alnylam Pharmaceuticals.
NCT07553442 is a Phase 2 study that is actively recruiting participants, run by Alnylam Pharmaceuticals. The registered enrollment target is 93 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (30% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07553442, a Phase 2 study, is actively recruiting participants, sponsored by Alnylam Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 93 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy, pharmacodynamics (PD), and safety of ALN-AGT01 RVR in participants with mild to moderate hypertension pretreated with zilebesiran.
Interventions
- DRUG Placebo
- DRUG Zilebesiran
- DRUG ALN-AGT01 RVR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 2026-04-27 |
| Est. Completion | 2028-10-01 |
| Phase | Phase 2 |
What NCT07553442 shows while recruiting
NCT07553442 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 93 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (30% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT07553442 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07553442 about?
NCT07553442 is a clinical study titled "A Study to Evaluate ALN-AGT01 RVR in Adult Patients With Mild to Moderate Hypertension Pretreated With Zilebesiran". The purpose of this study is to evaluate the efficacy, pharmacodynamics (PD), and safety of ALN-AGT01 RVR in participants with mild to moderate hypertension pretreated with zilebesiran.
What is the current status of trial NCT07553442?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 93 participants. The study started on 2026-04-27. Estimated completion is 2028-10-01.
What interventions are being tested in trial NCT07553442?
The interventions under investigation include: Placebo (DRUG), Zilebesiran (DRUG), ALN-AGT01 RVR (DRUG).
Who is sponsoring clinical trial NCT07553442?
This trial is sponsored by Alnylam Pharmaceuticals, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07553442's enrollment target sits among peer trials
93 766th of 2000 higher than 1,234 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02203526 · 93 participants · Phase 1
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma
- NCT03089554 · 93 participants · Phase 2
Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies
- NCT05000021 · 93 participants · NA
Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes
- NCT05489887 · 93 participants · Phase 2
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI